These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 29052617)

  • 1. ADHD, Smoking Withdrawal, and Inhibitory Control: Results of a Neuroimaging Study with Methylphenidate Challenge.
    Sweitzer MM; Kollins SH; Kozink RV; Hallyburton M; English J; Addicott MA; Oliver JA; McClernon FJ
    Neuropsychopharmacology; 2018 Mar; 43(4):851-858. PubMed ID: 29052617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of smoking abstinence on smoking-reinforced responding, withdrawal, and cognition in adults with and without attention deficit hyperactivity disorder.
    Kollins SH; English JS; Roley ME; O'Brien B; Blair J; Lane SD; McClernon FJ
    Psychopharmacology (Berl); 2013 May; 227(1):19-30. PubMed ID: 23247366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of attention-deficit/hyperactivity disorder (ADHD) treatment on smoking cessation intervention in ADHD smokers: a randomized, double-blind, placebo-controlled trial.
    Winhusen TM; Somoza EC; Brigham GS; Liu DS; Green CA; Covey LS; Croghan IT; Adler LA; Weiss RD; Leimberger JD; Lewis DF; Dorer EM
    J Clin Psychiatry; 2010 Dec; 71(12):1680-8. PubMed ID: 20492837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. OROS-methylphenidate or placebo for adult smokers with attention deficit hyperactivity disorder: racial/ethnic differences.
    Covey LS; Hu MC; Winhusen T; Weissman J; Berlin I; Nunes EV
    Drug Alcohol Depend; 2010 Jul; 110(1-2):156-9. PubMed ID: 20219292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toward personalized smoking-cessation treatment: Using a predictive modeling approach to guide decisions regarding stimulant medication treatment of attention-deficit/hyperactivity disorder (ADHD) in smokers.
    Luo SX; Covey LS; Hu MC; Levin FR; Nunes EV; Winhusen TM
    Am J Addict; 2015 Jun; 24(4):348-56. PubMed ID: 25659348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of smoking abstinence on adult smokers with and without attention deficit hyperactivity disorder: results of a preliminary study.
    McClernon FJ; Kollins SH; Lutz AM; Fitzgerald DP; Murray DW; Redman C; Rose JE
    Psychopharmacology (Berl); 2008 Mar; 197(1):95-105. PubMed ID: 18038223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methylphenidate normalizes frontocingulate underactivation during error processing in attention-deficit/hyperactivity disorder.
    Rubia K; Halari R; Mohammad AM; Taylor E; Brammer M
    Biol Psychiatry; 2011 Aug; 70(3):255-62. PubMed ID: 21664605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuroimaging of inhibitory control areas in children with attention deficit hyperactivity disorder who were treatment naive or in long-term treatment.
    Pliszka SR; Glahn DC; Semrud-Clikeman M; Franklin C; Perez R; Xiong J; Liotti M
    Am J Psychiatry; 2006 Jun; 163(6):1052-60. PubMed ID: 16741206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An exploration of site effects in a multisite trial of OROS-methylphenidate for smokers with attention deficit/hyperactivity disorder.
    Covey LS; Hu MC; Green CA; Brigham G; Hurt RD; Adler L; Winhusen T
    Am J Drug Alcohol Abuse; 2011 Sep; 37(5):392-9. PubMed ID: 21854282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Common and unique therapeutic mechanisms of stimulant and nonstimulant treatments for attention-deficit/hyperactivity disorder.
    Schulz KP; Fan J; Bédard AC; Clerkin SM; Ivanov I; Tang CY; Halperin JM; Newcorn JH
    Arch Gen Psychiatry; 2012 Sep; 69(9):952-61. PubMed ID: 22945622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Attention-deficit/hyperactivity disorder (ADHD) symptoms, craving to smoke, and tobacco withdrawal symptoms in adult smokers with ADHD.
    Berlin I; Hu MC; Covey LS; Winhusen T
    Drug Alcohol Depend; 2012 Aug; 124(3):268-73. PubMed ID: 22364776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methylphenidate for treating tobacco dependence in non-attention deficit hyperactivity disorder smokers: a pilot randomized placebo-controlled trial.
    Hurt RD; Ebbert JO; Croghan IT; Schroeder DR; Sood A; Hays JT
    J Negat Results Biomed; 2011 Jan; 10():1. PubMed ID: 21276244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of single-dose methylphenidate on resting-state network functional connectivity in ADHD.
    Silk TJ; Malpas C; Vance A; Bellgrove MA
    Brain Imaging Behav; 2017 Oct; 11(5):1422-1431. PubMed ID: 27734305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Age-dependent effects of acute methylphenidate on amygdala reactivity in stimulant treatment-naive patients with Attention Deficit/Hyperactivity Disorder.
    Bottelier MA; Schrantee A; Ferguson B; Tamminga HGH; Bouziane C; Kooij JJS; de Ruiter MB; Reneman L
    Psychiatry Res Neuroimaging; 2017 Nov; 269():36-42. PubMed ID: 28938219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First-Dose Methylphenidate-Induced Changes in Brain Functional Connectivity Are Correlated With 3-Month Attention-Deficit/Hyperactivity Disorder Symptom Response.
    Silberstein RB; Levy F; Pipingas A; Farrow M
    Biol Psychiatry; 2017 Nov; 82(9):679-686. PubMed ID: 28465019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Divergence by ADHD subtype in smoking cessation response to OROS-methylphenidate.
    Covey LS; Hu MC; Weissman J; Croghan I; Adler L; Winhusen T
    Nicotine Tob Res; 2011 Oct; 13(10):1003-8. PubMed ID: 21652734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploring longitudinal course and treatment-baseline severity interactions in secondary outcomes of smoking cessation treatment in individuals with attention-deficit hyperactivity disorder.
    Luo SX; Wall M; Covey L; Hu MC; Scodes JM; Levin FR; Nunes EV; Winhusen T
    Am J Drug Alcohol Abuse; 2018; 44(6):653-659. PubMed ID: 29370538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional magnetic resonance imaging of methylphenidate and placebo in attention-deficit/hyperactivity disorder during the multi-source interference task.
    Bush G; Spencer TJ; Holmes J; Shin LM; Valera EM; Seidman LJ; Makris N; Surman C; Aleardi M; Mick E; Biederman J
    Arch Gen Psychiatry; 2008 Jan; 65(1):102-14. PubMed ID: 18180434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methylphenidate normalises activation and functional connectivity deficits in attention and motivation networks in medication-naïve children with ADHD during a rewarded continuous performance task.
    Rubia K; Halari R; Cubillo A; Mohammad AM; Brammer M; Taylor E
    Neuropharmacology; 2009 Dec; 57(7-8):640-52. PubMed ID: 19715709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S
    CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.